Description
Recombinant monoclonal antibody to BCMA. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the alpaca peripheral blood lymphocytes B65. This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques.
Target
BCMA
Target Alias Names
CD269, BCM, TNFRSF17, Tumor necrosis factor receptor superfamily member 17, B-cell maturation protein
Isotype/Mimetic
IgA-Fc Fusion
Animal-Derived Biomaterials Used
No
Sequence Available
No
Original Discovery Method
recombinantly reformatted hybridoma (from pre-2020 immunisation)
Original Discovery Information Provided On Datasheet
Yes
Antibody/Binder Origins
Animal-dependent discovery (in vitro display, OR immunisation pre-2020), In vitro recombinant expression